Cargando…

41. PROGNOSTIC VALIDATION OF THE EANO ESMO CLASSIFICATION OF LEPTOMENINGEAL METASTASIS

BACKGROUND: The EANO ESMO guidelines have proposed a classification of leptomeningeal metastases (LM) based on clinical (typical/atypical), cytological (positive/negative/equivocal) and MRI (A linear, B nodular, C linear and nodular, D normal or hydrocephalus only) presentation. Type I LM is defined...

Descripción completa

Detalles Bibliográficos
Autores principales:	Le Rhun, Emilie, Devos, Patrick, Weller, Johannes, Seystahl, Katharina, Mo, Francesca, Compter, Annette, Sophie Berghoff, Anna, Jongen, Joost, Wolpert, Fabian, Rudà, Roberta, Brandsma, Dieta, van den Bent, Martin, Preusse, Matthias, Herrlinger, Ulrich, Weller, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Supplement Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7401337/ http://dx.doi.org/10.1093/noajnl/vdaa073.029

Ejemplares similares

Leptomeningeal metastasis from solid tumours: EANO–ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
por: Le Rhun, E., et al.
Publicado: (2023)

NEIM-13 THE PROGNOSTIC ROLE OF VENTRICULAR SIZE AND ITS DYNAMICS IN PATIENTS WITH LEPTOMENINGEAL METASTASIS FROM SOLID TUMORS
por: Le Rhun, Emilie, et al.
Publicado: (2023)

40. AN UPDATE ON THE DEVELOPMENT OF A NEW TOOL TO ASSESS RESPONSE IN LEPTOMENINGEAL METASTASIS
por: Weller, Michael, et al.
Publicado: (2020)

EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood
por: Weller, Michael, et al.
Publicado: (2020)

Whole brain radiotherapy combined with intrathecal liposomal cytarabine for leptomeningeal metastasis—a safety analysis and validation of the EANO-ESMO classification
por: Iglseder, Sarah, et al.
Publicado: (2022)

Author Correction: EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood
por: Weller, Michael, et al.
Publicado: (2022)

How we treat patients with leptomeningeal metastases
por: Le Rhun, Emilie, et al.
Publicado: (2019)

EANO guideline on rational molecular testing of gliomas, glioneuronal, and neuronal tumors in adults for targeted therapy selection
por: Capper, David, et al.
Publicado: (2023)

24. LOCAL TUMOR PROGRESSION IS A RISK FACTOR FOR POSTOPERATIVE SEIZURES IN PATIENTS WITH BRAIN METASTASIS
por: Grossenbacher, Bettina, et al.
Publicado: (2020)

Prescription preferences of antiepileptic drugs in brain tumor patients: An international survey among EANO members
por: van der Meer, Pim B, et al.
Publicado: (2021)

SURG-10. The evolving role of neurosurgery for central nervous system metastases in the era of personalized medicine
por: Karschnia, Philipp, et al.
Publicado: (2021)

Vascular endothelial growth factor (VEGF) in leptomeningeal metastasis: diagnostic and prognostic value
por: Herrlinger, U, et al.
Publicado: (2004)

Venous thromboembolic events in glioblastoma patients: An epidemiological study
por: Eisele, Amanda, et al.
Publicado: (2022)

MLTI-13. RESPONSE ASSESSMENT OF MELANOMA BRAIN METASTASES TREATED BY STEREOTACTIC RADIOTHERAPY OR IMMUNOTHERAPY OR BOTH: A COMPARISON OF RECIST 1.1, RANO AND iRANO CRITERIA
por: Le Rhun, Emilie, et al.
Publicado: (2019)

Liquid biopsy in central nervous system metastases: a RANO review and proposals for clinical applications
por: Boire, Adrienne, et al.
Publicado: (2019)

Response assessment and outcome of combining immunotherapy and radiosurgery for brain metastasis from malignant melanoma
por: Le Rhun, Emilie, et al.
Publicado: (2020)

Carcinomatous meningitis: Leptomeningeal metastases in solid tumors
por: Le Rhun, Emilie, et al.
Publicado: (2013)

The Overview of Practical Guidelines for Gliomas by KSNO, NCCN, and EANO
por: Kim, Young Zoon, et al.
Publicado: (2022)

Nachwuchsförderung durch die European Society for Medical Oncology (ESMO): Erfahrungen aus dem ESMO Young Oncologist Committee (YOC)
por: Oing, Christoph, et al.
Publicado: (2020)

Sex-specific aspects of epidemiology, molecular genetics and outcome: primary brain tumours
por: Le Rhun, Emilie, et al.
Publicado: (2020)

Associations of levetiracetam use with the safety and tolerability profile of chemoradiotherapy for patients with newly diagnosed glioblastoma
por: Seystahl, Katharina, et al.
Publicado: (2022)

Advances in the diagnosis, evaluation, and management of leptomeningeal disease
por: Sener, Ugur, et al.
Publicado: (2021)

Introducing pro and con discussions in ESMO Open—Cancer Horizons
por: Zielinski, C., et al.
Publicado: (2022)

MLTI-19. VENOUS THROMBOEMBOLIC EVENTS IN PATIENTS WITH BRAIN METASTASES: THE PICOS SCORE
por: Wolpert, Fabian, et al.
Publicado: (2019)

Perioperative imaging in patients treated with resection of brain metastases: a survey by the European Association of Neuro-Oncology (EANO) Youngsters committee
por: Kiesel, Barbara, et al.
Publicado: (2020)

Prognostic assessment in patients operated for brain metastasis from systemic tumors
por: Grossenbacher, Bettina, et al.
Publicado: (2023)

NEIM-01 INCIDENCE AND DIAGNOSTIC TECHNIQUES FOR LEPTOMENINGEAL DISEASE IN PATIENTS WITH BRAIN METASTASIS
por: Henry, Katie, et al.
Publicado: (2022)

21. A PHASE II TRIAL OF COMPREHENSIVE TREATMENT BASED ON RADIOTHERAPY IN LEPTOMENINGEAL METASTASIS
por: Yang, Siran, et al.
Publicado: (2020)

LMD-10. The role of immune checkpoint inhibitors in leptomeningeal disease: a systematic review
por: Palmisciano, Paolo, et al.
Publicado: (2021)

LMD-22. Clinicopathological spectrum of leptomeningeal metastases: A 3 year retrospective study
por: Pahwa, Saloni, et al.
Publicado: (2021)

LMD-21. Headache Improvement Predicts Survival after CSF diversion in Leptomeningeal Disease
por: Robin, Adam, et al.
Publicado: (2021)

OTME-17. Single cell characterization of the immune microenvironment of melanoma brain and leptomeningeal metastases
por: Smalley, Inna, et al.
Publicado: (2021)

SPCR-02 NEUROCOGNITIVE FUNCTION IN PATIENTS WITH LEPTOMENINGEAL METASTASIS TREATED WITH PROTON CRANIOSPINAL IRRADIATION
por: Correa, Denise, et al.
Publicado: (2022)

Molecular diagnostic tools for the World Health Organization (WHO) 2021 classification of gliomas, glioneuronal and neuronal tumors; an EANO guideline
por: Sahm, Felix, et al.
Publicado: (2023)

56. TUMOR-HOMING STEM CELL THERAPY INHIBITS THE PROGRESSION OF BREAST CANCER LEPTOMENINGEAL CARCINOMATOSIS
por: Jiang, Wulin, et al.
Publicado: (2020)

11. ASSOCIATION OF TUMOR EXPOSURE TO CEREBROSPINAL FLUID SPACES TO LEPTOMENINGEAL DISEASE IN PATIENTS WITH BRAIN METASTASES
por: Patel, Kunal, et al.
Publicado: (2020)

ETMM-03. CANCER CELLS DEPLOY LIPOCALIN- 2 TO COLLECT LIMITING IRON IN LEPTOMENINGEAL METASTASIS
por: Chi, Yudan, et al.
Publicado: (2021)

LMD-02. Cerebrospinal Fluid Diversion for Metastatic Leptomeningeal Carcinomatosis: Palliative, Procedural and Oncologic Outcomes
por: Bander, Evan D, et al.
Publicado: (2021)

LMD-19. Anatomic and Surgical Factors Predict Development of Leptomeningeal Disease in Patients with Metastatic Melanoma
por: Lowe, Stephen, et al.
Publicado: (2021)

BSCI-08 NEURONAL MIMICRY PROMOTES BREAST CANCER LEPTOMENINGEAL METASTASIS FROM BONE MARROW
por: Whiteley, Andrew, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_06589jtuau5vus51u6kp6a88ka